Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes

Cancer

Volumn 116, Issue 10, 2010, Pages 2372-2381

  Wimazal, Friedrich ^a,b   Germing, Ulrich ^c   Kundi, Michael ^a   Noesslinger, Thomas ^d   Blum, Sabine ^c   Geissler, Philipp ^a   Baumgartner, Christian ^a   Pfeilstoecker, Michael ^d   Valent, Peter ^a,e   Sperr, Wolfgang R ^a,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Ludwig Boltzmann Society   (Austria)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Basophils; Eosinophils; International prognostic scoring system; Lactate dehydrogenase; Myelodysplastic syndromes; Prognostication

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BASOPHILIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EOSINOPHILIA; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; BASOPHIL; DISEASE COURSE; FOLLOW UP; LEUKOCYTE COUNT; LEUKOCYTE DISORDER; LEUKOPENIA; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; BASOPHILS; DISEASE PROGRESSION; EOSINOPHILIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; LEUKOCYTE DISORDERS; LEUKOPENIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK ASSESSMENT;

EID: 77952556491     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25036     Document Type: Article

References (30)

1. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1-16.
2. Strom SS, Velez-Bravo V, Estey EH. Epidemiology of myelodysplastic syndromes. Semin Hematol. 2008;45:8-13.
3. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10:258-269.
4. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727-736.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
6. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of Haematopoietic and Lymphoid Tissues, Pathology and Genetics, World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001:61-73.
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
8. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52-59.
9. Wimazal F, Sperr WR, Kundi M, et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res. 2001;25:287-294.
10. Germing U, Hildebrandt B, Pfeilstocker M, et al. Refinement of the International Prognostic Scoring System (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223-2231.
11. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385-4395.
12. Pfeilstocker M, Karlic H, Nosslinger T, et al. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma. 2007;48: 1900-1909.
13. van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067-1077.
14. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510.
15. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705-1714. (Pubitemid 46668530)
16. Wimazal F, Sperr WR, Kundi M, et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol. 2008;19:970-976. (Pubitemid 351627316)
17. Denburg JA, Browman G. Prognostic implications of basophil differentiation in chronic myeloid leukemia. Am J Hematol. 1988;27:110-114.
18. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446. (Pubitemid 18076421)
19. Gomez GA, Sokal JE, Walsh D. Prognostic features at diagnosis of chronic myelocytic leukemia. Cancer. 1981;47:2470-2477. (Pubitemid 11127639)
20. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.
21. Steegmann JL, Odriozola J, Rodriguez-Salvanes F, et al. Stage, percentage of basophils at diagnosis, hematologic response within 6 months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica. 1999;84:978-987.
22. Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003;101:3386-3390.
23. Fureder W, Schernthaner GH, Ghannadan M, et al. Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest. 2001;31:894-901.
24. Shibata K, Watanabe M, Yano H, Matsuzaki M, Funai N, Sano M. Importance of basophilia in haematopoietic disorders. Haematologia (Budap). 1998;29:241-253.
25. Wimazal F, Baumgartner C, Sonneck K, et al. Mixed basophil/ eosinophil transformation in chronic myelomonocytic leukemia. Eur J Clin Invest. 2008;38:447-455.
26. Therneau TM. Extending the Cox Model. Technical Report Series, no. 58. Rochester, Minn: Section of Biostatistics, Mayo Clinic; 1996.
27. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133:468-492.
28. Gotlib J, Cross NC, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;19:535-569. (Pubitemid 43869477)
29. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev. 2009;23:157-165.
30. Varkonyi J, Jakab L, Zalatnay A, Nagy P, Vamoss R, Szombathy T. Polychondritis terminating in eosinophilic leukemia. Pathol Oncol Res. 1997;3:135-138.